Source-grounded facts extracted from CORCEPT THERAPEUTICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CORCEPT THERAPEUTICS INC shareholders approved Approval of amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan at the 2026-05-21 meeting.
“Proposal 4 - The amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan was approved. For 53,163,364 Against 23,867,363 Abstain 263,730 Broker Non-Votes 15,975,718”
CORCEPT THERAPEUTICS INC shareholders approved Advisory approval of the compensation of named executive officers at the 2026-05-21 meeting.
“Proposal 3 - The compensation of named executive officers was approved, on an advisory basis. For 72,511,429 Against 4,560,385 Abstain 222,643 Broker Non-Votes 15,975,718”
CORCEPT THERAPEUTICS INC shareholders approved Ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-21 meeting.
“Proposal 2 - The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. For 92,656,473 Against 569,010 Abstain 44,692 Broker Non-Votes —”
CORCEPT THERAPEUTICS INC shareholders approved Election of eight directors to hold office until 2027 annual meeting at the 2026-05-21 meeting.
“Proposal 1 - Election of Directors. The following directors were elected to serve until the Company’s 2027 annual meeting of stockholders. Director For Withheld Broker Non-Votes Gregg Alton 67,977,943 9,316,514 15,975,718 G. Leonard Baker, Jr. 64,912,506 12,381,951 15,975,718 Joseph K. Belanoff, M.D. 76,965,512 328,945 15,975,718 David L. Mahoney 51,078,278 26,216,179 15,975,718 Joshua M. Murray 76,753,606 540,851 15,975,718 Kimberly Park 70,288,833 7,005,624 15,975,718 Daniel N. Swisher, Jr. 67,594,098 9,700,359 15,975,718 James N. Wilson 72,730,017 4,564,440 15,975,718”
CORCEPT THERAPEUTICS INC reported the quarter ended March 31, 2026 results: revenue $164.9 million, net income Net loss of $31.8 million, EPS Net loss per common share (diluted) was $0.30. Guidance raised.
“• Revenue of $164.9 million, compared to $157.2 million in first quarter 2025 • Increase in 2026 revenue guidance to $950 – $1,050 million • Net loss of $31.8 million, compared to net income of $20.5 million in first quarter 2025 • Cash and investments of $515.4 million at March 31, 2026 • LifyorliTM (relacorilant) approved by FDA in March 2026 for the treatment of patients with platinum-resistant ovarian cancer REDWOOD CITY, Calif., (April 30, 2026) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2026. Financial Results Corcept’s first quarter 2026 revenue was $164.9 million, compared to $157.2 million in the first quarter of 2025. First quarter 2026 operating expenses were $214.5 million, compared to $153.8 millio”
CORCEPT THERAPEUTICS INC entered into Sublease with Zuora, Inc. valued at base rent of an average of $1.4 million annually and Shared Amenities Space base rent of an average (effective 2024-04-12).
“On April 12, 2024, Corcept Therapeutics Incorporated (“Corcept”) entered into a sublease (the “Sublease”) with Zuora, Inc. for a portion of the premises located at 101 Redwood Shores Parkway, Redwood City, California 94065 (the “Building”).”
CORCEPT THERAPEUTICS INC reported the year ended December 31, 2023 results: revenue $482.4 million, net income $106.1 million, EPS $0.94. Guidance reaffirmed.
“and year ended December 31, 2023. Financial Results • Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022 • Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022 • Reiterated 2024 revenue guidance of $600 – $630 million • Fourth quarter net income of $31.4 million, compared to $16.6 million in fourth”
CORCEPT THERAPEUTICS INC reported the quarter and year ended December 31, 2023 results: revenue $135.4 million, net income $31.4 million, EPS $0.28. Guidance reaffirmed.
“today reported its results for the quarter and year ended December 31, 2023. Financial Results • Fourth quarter revenue of $135.4 million”
CORCEPT THERAPEUTICS INC reported fiscal year 2024 results: revenue $600 – $630 million. Guidance initiated.
“Financial Update • Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022 • Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022 • 2024 revenue guidance of $600 – $630 million • Cash and investments of $425.4 million as of December 31, 2023 • Announcement of $200 million stock repurchase program “As the true prevalence of hypercortisolism and its devastating impact become better understood, physicians are identifying and treating more patients”
CORCEPT THERAPEUTICS INC reported year ended December 31, 2023 results: revenue $482.4 million.
“Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022”
CORCEPT THERAPEUTICS INC reported quarter ended December 31, 2023 results: revenue $135.4 million.
“Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022”
CORCEPT THERAPEUTICS INC: Amended and restated bylaws to allow postponement/rescheduling/cancellation of annual meetings, enhance director nomination and business proposal requirements, and address proxy solicitation mechanics (effective 2023-12-05).
“On December 5, 2023, the Board of Directors (the “Board”) of Corcept Therapeutics Incorporated (the “Company”) approved and adopted an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of December 5, 2023.”
CORCEPT THERAPEUTICS INC reported the quarter ended September 30, 2023 results: revenue $123.6 million, net income $31.4 million, EPS $0.28 (diluted). Guidance raised.
“and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended September 30, 2023. Financial Results • Revenue of $123.6 million, a 22 percent increase from third quarter 2022 • Increase in 2023 revenue guidance to $470 – $480 million, from $455 – $470 million • Net income per common share of $0.28”
CORCEPT THERAPEUTICS INC reported the quarter ended June 30, 2023 results: revenue $117.7 million, net income $27.5 million, EPS $0.25 (diluted). Guidance raised.
“metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended June 30, 2023. Financial Results • Revenue of $117.7 million, a 14 percent increase from second quarter 2022 • Increase in 2023 revenue guidance to $455 – $470 million, from $435 – $455 million • Net income per common share of $0.25”
CORCEPT THERAPEUTICS INC: Amendment and restatement of the Amended and Restated Certificate of Incorporation to allow officer exculpation under Delaware law (effective 2023-05-22).
“At the 2023 annual meeting of stockholders of Corcept Therapeutics Incorporated (the “Company”) held on May 19, 2023 (the “Annual Meeting”), the Company’s stockholders approved an amendment and restatement of the Company’s Amended and Restated Certificate of Incorporation (the “ Restated Certificate of Incorporation”) to reflect Delaware law provisions allowing officer exculpation.”
CORCEPT THERAPEUTICS INC shareholders approved Approval of the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions allowing officer exculpation at the 2023-05-19 meeting.
“Proposal 5 — The amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions allowing officer exculpation was approved. For 62,951,214 Against 7,616,002 Abstain 214,178 Broker Non-Votes 19,213,069”
CORCEPT THERAPEUTICS INC shareholders approved Advisory vote on the frequency of the vote on compensation of named executive officers at the 2023-05-19 meeting.
“Proposal 4 — Advisory vote on the frequency of the vote on compensation of named executive officers. 3 years 28,623,378 2 years 127,477 1 year 41,624,266 Abstain 406,273 Broker Non-Votes 19,213,069”
CORCEPT THERAPEUTICS INC shareholders approved Advisory vote to approve the compensation of the Company's named executive officers at the 2023-05-19 meeting.
“Proposal 3 — Advisory vote to approve the compensation of named executive officers. For 69,095,025 Against 1,450,799 Abstain 235,570 Broker Non-Votes 19,213,069”
CORCEPT THERAPEUTICS INC shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-19 meeting.
“Proposal 2 — The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. For 88,986,042 Against 923,595 Abstain 84,826 Broker Non-Votes”
CORCEPT THERAPEUTICS INC shareholders approved Election of nine directors to hold office until the 2024 annual meeting of stockholders at the 2023-05-19 meeting.
“Proposal 1 — Election of Directors. The following directors were elected to serve until the Company's 2024 annual meeting of stockholders. Director For Withheld Broker Non-Votes Gregg Alton 68,542,369 2,239,025 19,213,069 G. Leonard Baker, Jr. 66,577,355 4,204,039 19,213,069 Joseph K. Belanoff, M.D. 70,198,149 583,245 19,213,069 Gillian M. Cannon, Ph.D. 68,240,572 2,540,822 19,213,069 David L. Mahoney 68,932,261 1,849,133 19,213,069 Joshua M. Murray 70,337,272 444,122 19,213,069 Kimberly Park 63,533,589 7,247,805 19,213,069 Daniel N. Swisher, Jr. 67,206,994 3,574,400 19,213,069 James N. Wilson 66,198,888 4,582,506 19,213,069”
CORCEPT THERAPEUTICS INC reported the quarter ended March 31, 2023 results: revenue $105.7 million, net income $15.9 million, EPS $0.14 (diluted). Guidance raised.
“Financial Results • Revenue of $105.7 million, compared to $93.7 million in first quarter 2022 • Raised 2023 revenue guidance to $435 – $455 million, from $430 – $450 million • Net income per common share of $0.14 (diluted), compared to $0.20 in first quarter 2022 • Cash and investments of $465.1 million as of March 31, 2023 • Purchase of 6.6 million shares of Corcept common stock for $145.4 million in April 2023 Corcept’s first quarter 2023 revenue was $105.7 million, compared to $93.7 million in the first quarter of 2022. First quarter operating expenses were $90.8 million, compared to $66.9 million in the first quarter of 2022, due to increased spending on clinical trials and sales and marketing activities and to support the expansion of our clinical development and commercial teams. Net income was $15.9 million in the first quarter of 2023 compared to $22.8 million in the same period last year.”
CORCEPT THERAPEUTICS INC reported the quarter and year ended December 31, 2022 results: revenue $103.1 million, net income $16.6 million, EPS $0.14 per diluted common share. Guidance reaffirmed.
“Fourth quarter revenue of $103.1 million, compared to $98.8 million in fourth quarter 2021 • 2022 revenue of $401.9 million, compared to $366.0 million in 2021 • 2023 revenue guidance of $430 – $450 million • Fourth quarter diluted net income per common share of $0.14, compared to $0.26 in fourth quarter 2021 • 2022 diluted net income per common share of $0.87, compared to $0.89 in 2021 • Cash and investments of $436.6 million, compared to $335.8 million at December 31, 2021 Corcept’s fourth quarter 2022 revenue was $103.1 million, compared to $98.8 million in the fourth quarter of 2021. Revenue for the full year was $401.9 million, compared to $366.0 million in 2021. The company expects 2023 revenue of $430 – $450 million. Net income was $16.6 million in the fourth quarter of 2022, compared to $32.1 million in the fourth quarter of 2021. For the full year, it was $101.4 million compared to $112.5 million in 2021. Cash and investments of $436.6 million at December 31, 2022 compared to”
CORCEPT THERAPEUTICS INC reported the quarter ended September 30, 2022 results: revenue $101.7 million, net income $34.6 million, EPS $0.30. Guidance reaffirmed.
“Revenue of $101.7 million, compared to $96.1 million in third quarter 2021 • Tightened 2022 revenue guidance of $400 – $410 million • Diluted net income per common share of $0.30, compared to $0.24 in third quarter 2021”
Andreas Grauer changed role as senior medical advisor at CORCEPT THERAPEUTICS INC.
“On August 10, 2021, Andreas Grauer, M.D. separated from his position as Chief Medical Officer of Corcept Therapeutics Incorporated (the “Company”). Dr. Grauer has agreed to serve as a senior medical advisor to the Company to assist with its development programs and to help transition his responsibilities to the Company’s Chief Development Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.